<DOC>
	<DOCNO>NCT02688400</DOCNO>
	<brief_summary>Osteoarthritis ( OA ) knee frequent cause knee pain age 50 year . OA joint disease characterise articular cartilage loss associate structural change cartilage adjacent structure . The main symptom pain functional disability . The goal OA therapy decrease pain maintain improve joint function . There evidence diacerein symptomatic structural effect cartilage , clinical study suggest diacerein therapy significantly decrease OA symptom compare placebo . Diacerein show inhibit interleukine-1 ( IL-1β ) , down-regulated IL-1β stimulate secretion metalloproteinases aggrecanases , thereby prevent breakdown cartilage enzyme . Diacerein effect synthesis prostaglandin , therefore effect upper intestinal tract . The purpose phase III-IV international , multicentre , double-blind , non-inferiority , randomise , control study determine efficacy safety diacerein vs. celecoxib symptom 6 month treatment , structural change 2 year treatment knee OA patient assess magnetic resonance imaging ( MRI ) .</brief_summary>
	<brief_title>Effect Diacerein v Celecoxib Symptoms Structural Changes Symptomatic Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Diacetylrhein</mesh_term>
	<criteria>Men woman least 50 year age ; Patients follow ambulatory clinic ; Patients present primary OA knee accord American College Rheumatology ( ACR ) criterion ; Patients OA radiological stage 2 3 accord KellgrenLawrence ; Patients minimum joint space width ≥ 2 mm medial tibiofemoral compartment stand knee Xray ( MRI structural study ) ; Patients knee pain day month enter study ; Patients VAS pain score ( 0100 mm ) walk flat surface ≥ 40 mm ( Visit 1 ( Screening ) Visit 2 ( Inclusion Visits ) ) ; Patients clinically significant laboratory abnormality judgment investigator ; Female patient postmenopausal confirm amenorrhea least one year enter study underwent tubal ligation , oophorectomy hysterectomy must agree hormonal ( folliculostimulating hormone [ FSH ] ) dosage Screening visit ; Patients agree sign Informed Consent Form prior studyrelated activity clearly inform method constraint ; Patients take part another clinical study ; Patients agree respect protocol attend visit relate study . Criteria related individual characteristic patient Patients secondary knee OA ; Patients know hypersensitivity Diacerein anthraquinonecontaining product , hypersensitivity Celecoxib , demonstrate allergictype reaction sulphonamides , experience asthma , urticaria allergictype reaction take sulphonamides , aspirin ( acetyl salicylic acid [ ASA ] ) , lactose , nonsteroidal antiinflammatory drug [ NSAIDs ] , acetaminophen paracetamol ; Patients know history diarrhoea , particularly 65 year age old ; Patients active malignancy type history malignancy within last five year basal cell carcinoma ; Patients bone articular disease ( antecedent and/or current sign ) ; chondrocalcinosis , Paget 's disease ipsilateral limb target knee , rheumatoid arthritis , aseptic osteonecrosis , gout , septic arthritis , ochronosis , acromegaly , haemochromatosis , Wilson 's disease , osteochondromatosis , seronegative spondyloarthropathy , mixed connective tissue disease , collagen vascular disease , psoriasis , inflammatory bowel disease ; Pain part body great knee pain could interfere evaluation index joint ; Patients fibromyalgia ; Patients isolate knee lateral compartment OA define joint space loss lateral compartment ; Patients Class IV functional capacity use American Rheumatism Association criterion ; Patients surgery low limb arthroscopy , aspiration lavage low limb joint within 180 day Inclusion Visit ( Visit 2 ) ; Patients meniscal surgery study knee ; Patients undergone total knee replacement contralateral knee within 180 day prior Screening Visit ( Visit 1 ) ; Patients comorbid condition joint deformity restrict knee function ; Patients history heart attack stroke , serious disease heart congestive heart failure ( functional class IIIV New York Heart Association [ NYHA ] ) ; Patients significant risk factor heart attack stroke assess carefully . Risk factor heart attack stroke include high blood pressure ( treat untreated ) , high cholesterol , diabetes smoke . The global risk assessment assess use American Heart Association ( AHA ) assessment cardiovascular ( CV ) risk table . Patients high risk CV event , accord table , exclude ; Patients significant disease condition , include emotional psychiatric disorder substance abuse , opinion Investigator , likely alter appreciation OA symptoms patient 's ability complete study ; Patients history illness , opinion Investigator , might confound result study pose additional risk patient ; Patients poorly control diabetes mellitus define Haemoglobin A1c level &gt; 8 % ; Patients poorly control hypertension ( sustain Systolic Blood Pressure &gt; 150 mmHg Diastolic Blood Pressure &gt; 95 mmHg ) ; Patients active acute chronic infection require antimicrobial therapy , serious viral ( e.g. , hepatitis , herpes zoster , HIV positivity ) fungal infection ; Patients history recurrent upper gastrointestinal ( UGI ) ulceration active inflammatory bowel disease ( e.g. , Crohn 's disease ulcerative colitis ) , significant coagulation defect , condition , Investigator 's opinion might preclude chronic use Celecoxib Diacerein . Patients may , Investigator 's discretion , take proton pump inhibitor ( PPI ) antacid daily require , 2 hour period intake study medication intake PPI antacid ; Patients diagnose treated esophageal , gastric , pyloric channel , duodenal ulceration within 30 day prior receive first dose study medication ; Patients chronic liver kidney disease , define aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.0 time upper limit normal ( ULN ) blood urea nitrogen ( BUN ) serum creatinine &gt; 2.0 time ULN , Screening Visit ( Visit 1 ) ; Patients history intolerance acetaminophen paracetamol , opioids opioid combination felt adequate nonantiinflammatory rescue analgesic regimen safely prescribe ; Patients history alcohol substance abuse within last 3 year ; Patients receive investigational drug within 30 day 5 halflives ( whichever great ) prior Inclusion Visit ( Visit 2 ) ; Patients plan surgery study ; Female patient breastfeed ; Patients impossibility take part total duration study attend visit ; Patients unable give inform consent ; Patients respect acetaminophen paracetamol washout period 48 hour NSAID washout period 1 week Inclusion Visit ( Visit 2 ) . TreatmentRelated Exclusion : Patients use corticosteroid ( oral , injectable ; exception intraarticular/soft tissue injection exclusion target knee ) , indomethacin , therapeutic dose glucosamine , chondroitin sulphate Diacerein AvocadoSoybean Unsaponifiables ( ASU ) 12 week precede inclusion ( intraarticular injection corticosteroid contralateral knee allow study ) ; Patients use hyaluronic acid ( intraarticular target knee ) 26 week precede inclusion ; Patients use natural health product ( e.g . capsaicin , boswellia , willow bark ) , creams analgesic gel ( e.g . camphor alcohol base gel ) one week precede inclusion ; Patients use natural health product susceptible increase risk bleeding ( e.g . garlic , dong quai , etc . ) one week precede inclusion ; Patients receive radioactive synovectomy ( target knee ) 12 week precede inclusion ; Patients take NSAIDs want stop study ; If treatment osteoporosis ( bisphosphonates , selective estrogen receptor modulators [ SERMS ] , thyroidstimulating hormone [ TSH ] ) necessary , continue , unmodified , entire duration study ; Patients use compound contain nonapproved agent arthritis agent claim posse disease/structuremodifying property 14 day prior Inclusion Visit ( Visit 2 ) ; Patients use medication matrix metalloproteinase ( MMP ) inhibitory property ( e.g . tetracycline structurally related compound ) within 28 day prior Inclusion Visit ( Visit 2 ) ; Patients require acetaminophen paracetamol daily dos &gt; 2000 mg ( 2g ) regular basis ; Patients take laxative , lithium carbonate , phenytoin anticoagulant ( exception ASA maximum daily dose 325 mg ) ; Patients receive chondrocyte transplant underwent type cartilage repair procedure target joint ; Patients use oral topical coxibs ; Patients use calcitonin ; Patients use immunosuppressive drug . CriteriaRelated Magnetic Resonance Imaging ( MRI ) : Patients present counterindication MRI examination ; Patients whose Inclusion Visit cartilage volume calculate MRI due advance OA disease ; Patients whose Inclusion Visit cartilage volume calculate MRI due presence large fat pad technical reason ; Patients study knee enter MRI magnet ; Patients abnormal Inclusion Visit finding and/or condition , , Investigator 's judgment , might increase risk patient decrease chance obtain satisfactory data MRI achieve objective study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Osteoarthritis , Knee</keyword>
	<keyword>Diacerein</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Phase III</keyword>
	<keyword>Phase IV</keyword>
	<keyword>Phase III-IV</keyword>
	<keyword>Canada</keyword>
	<keyword>Spain</keyword>
	<keyword>Austria</keyword>
	<keyword>Czech Republic</keyword>
	<keyword>WOMAC</keyword>
</DOC>